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MicroarrayAnalyzing gene expression data at the gene set level greatly improves feature extraction and data interpretation.
Currently most efforts in gene set analysis are focused on differential expression analysis — ﬁnding gene sets
whose genes show ﬁrst-order relationship with the clinical outcome. However the regulation of the biological
system is complex, and much of the change in gene expression dynamics do not manifest in the form of differ-
ential expression. At the gene set level, capturing the change in expression dynamics is difﬁcult due to the com-
plexity and heterogeneity of the gene sets. Here we report a systematic approach to detect gene sets that show
differential coordination patterns with the rest of the transcriptome, as well as pairs of gene sets that are differ-
entially coordinated with each other. We demonstrate that the method can identify biologically relevant gene
sets, many of which do not show ﬁrst-order relationship with the clinical outcome.com.edu (Y. Bai).
rights reserved.© 2011 Elsevier Inc. All rights reserved.1. Introduction
Analyzing microarray gene expression data at the gene set level,
rather than at the single gene level, has proven to be an effective ap-
proach to extract valuable information for the elucidation of biological
mechanisms, and for the selection of genes to build classiﬁcation
models for diseases [1]. Currently, the dominant approaches in gene
set analysis focus on identifying gene setswhose genes are differentially
expressed between the control and treatment groups. A number of
methods compare the distribution of certain test statistics related to dif-
ferential expression against the background distribution [2–5]. To
address the issue of within-gene set heterogeneity, methods were de-
veloped to select subsets of genes for gene set scoring [6,7], utilize co-
variance structure [8], or incorporate other types of data [9]. Some of
the methods were reviewed and compared [1,10]. Most of the gene
set analysis methods can be further classiﬁed into two major sub-clas-
ses— those based on gene label permutation (competitive hypotheses),
and those based on sample permutation (self-contained hypotheses)
[1,10].
The aforementioned approaches focus on ﬁnding gene sets show-
ing ﬁrst-order relationships with the clinical outcome. However it is
well-established that higher-order relationships exist between gene
expression and the clinical outcome [11]. Capturing higher-orderrelationships at the gene set level can yield information that is not
revealed by the regular gene set analysis methods. There is difﬁculty
capturing such higher-order relationships at the gene set level,
because the majority of gene sets are not coherent in terms of expres-
sion [12]. Rather, as some authors documented, certain genes assume
more important roles in the regulation at the expression level [13].
Currently there are only a few works published in the area of ﬁnding
higher-order relationships at the gene set level. Choi and Kendziorski
proposed a method that focuses on within-gene set correlation
changes between treatment groups [14], which doesn't consider
changes of relationship between gene sets. Cho et al. proposed a
method to measure differential co-expression between pairs of gene
sets, which is based on the similarity of sample correlations measured
on individual gene sets [15]. This method doesn't test the global hy-
pothesis of whether a gene set is differentially regulated under differ-
ent treatment conditions.
Here we present a systematic approach named Gene Set Differential
CoordinationAnalysis (GSDCA). The reasonwe use theword “coordina-
tion”, rather than “co-expression”, is because of the lack of coherence in
the expression of the genes within gene sets [12]. Our approach allows
genes within a gene set to contribute at different levels based on the
correlation structure of the data. The method systematically tests a se-
ries of hypotheses: (1) test the hypothesis that a gene set is differential-
ly coordinated with the rest of the transcriptome between treatment
groups. (2) Test the hypothesis that a pair of gene sets is differentially
coordinated with each other between treatment groups. (3) Select
genes that are major contributors to the differential coordination.
The R code is available at http://userwww.service.emory.edu/~tyu8/
GSDCA/.
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2.1. The genome-wide index of correlation (GIOC) function of a gene set
In order to deﬁne a proﬁle of a gene set that's invariant to the number
of samples in each treatment group, we use the GIOC function, which is
deﬁned on the discrete space of all themeasured genes. A primitive ver-
sion of theGIOC functionwas deﬁned in our previouswork [16]. Howev-
er, we found that that version of GIOC function doesn't suit the need of
hypotheses testing between treatment conditions. The main reason is
that the overall distribution of the correlations between genes may be
different under different treatment conditions, caused by changes in
biological regulations, different levels ofmeasurement noise, or different
sample size. In the currentworkwedeﬁne a newGIOC function anda set
of testing procedures suitable for between-treatment group testing.
A key assumption of the GIOC function is that not all gene–gene cor-
relations are biologically relevant. This is based on the fact that some
genes are not regulated at the transcription level, and the majority of
gene pairs are not co-regulated [12,13,17,18].
First, for every gene gi in the gene collection G of the dataset, we
ﬁnd its highest absolute correlation with the genes in gene set S,
ci ¼ maxgk∈S corr gi; gkð Þj j:
This is similar to the single linkage distance measure in clustering.
Secondly, we transform the raw scores ci using a sigmoid function,
si ¼ 1−
1
1þ eα ci−δð Þ :
The motivation for such a transformation is to accommodate po-
tential differences in the overall distribution of the correlations
caused by varying noise levels and/or sample size difference between
treatment groups. In this report, we use the 97.5th percentile of the
cis of the genes not belonging to the gene set as δ, and select α such
that the 95th percentile receive the weight of 0.05 (maximum possi-
ble weight is one). Using this partially rank-based transformation, the
top 2.5% of the genes receive weights between 0.5 and 1, and the next
2.5% of the genes receive weights between 0.05 and 0.5. The rest 95%
of the genes receive weights of b0.05.
Thirdly, the sis are normalized to have sum one,
wi ¼ si=∑j∈G S j:
The resulting proﬁle w, which resembles a probability distribu-
tion, is denoted the GIOC proﬁle of gene set S.
2.2. Measuring the coordination change of a gene set between treatment
groups
In order to measure the change in the GIOC proﬁle of a gene set be-
tween different treatment groups, we use the metric distance deﬁned
by Comaniciu et al. based on Bhattacharyya coefﬁcient [19],
D ¼ 1−∑i∈G
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
w group1i w
group2
i
q 1=2
;
which is normally used to measure the distance between probability
distributions. We randomly permute the sample labels K times and
compute the distances {D(k)}k=1,…,K. The proportion of the sampled
permutations with distance larger than the observed distance is taken
as the p-value of the one-sided test,
p ¼ 1
K
∑Kk¼1I D
kð Þ≥D
 
;where I(A) is the indicator function which is 1 if A is true and 0 other-
wise. The workﬂow is illustrated in Supporting Fig. 1.
2.3. Identifying changes of coordination between pairs of gene sets
For two gene sets S1 and S2, we ﬁrst ﬁnd their GIOC proﬁles in treat-
ment group 1, w1
group1 and w2
group1, respectively. We then ﬁnd the dis-
tance between the two GIOC proﬁles,
Dgroup1S1 ;S2 ¼ 1−∑i∈G
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
wgroup11;i w
group1
2;i
q 1=2
:
Similarly, we ﬁnd the distance between their GIOC proﬁles in
treatment group 2. We then take the difference of the distances,
ΔDS1 ;S2 ¼ D
group2
S1 ;S2
−Dgroup1S1 ;S2 ;
as a measure of change in coordination between the pair of gene sets
across the treatment groups. To assess the signiﬁcance of the change,
we randomly permute the treatment group labels K times and compute
the distances {ΔDS1,S2
(k) }k=1,…,K. We take
p ¼ 2
K
min ∑Kk¼1I ΔD kð Þ≥ΔD
 
;∑Kk¼1I ΔD
kð Þ≤ΔD
  
as the p-value of the two-sided test. The direction of change can be de-
termined by the tail of the distribution the observed statistic falls onto.
The workﬂow is illustrated in Supporting Fig. 2.
2.4. Identifying the genes that are major contributors to the differential
coordination of a gene set
To identify genes that aremajor contributors to the differential coor-
dination of a gene set, we focus on the gene–gene correlations that help
deﬁne the GIOC proﬁle. First, for every gene gm in the gene set S, we cre-
ate an indicator vector ym to denote whether it is the nearest neighbor
(highest absolute correlation) within S to other genes,
ymi ¼ I m ¼ argmax j∈S corr gj; gi
   ;∀gi ∈G−S:
Secondly, between the treatment groups, for every gene gm in the
gene set S, we ﬁnd the difference between its correlations with other
genes, focusing on those to which gm is the nearest neighbor within S
in either treatment group. Another indicator vector is created for this
purpose,
zmi ¼ I y group1mi þ y group2mi ≥1
 
;∀gi ∈G−S:
We then ﬁnd the mean absolute difference between the absolute
values of the correlation coefﬁcients,
dm ¼
∑i:gi∈G−S zmi corr gm; gið Þj j
group1− corr gm; gið Þj jgroup2
 
∑i:gi∈G−S zmi
:
Thirdly, the signiﬁcance of dm is determined through a randomiza-
tion test. We permute the sample labels K times to obtain {dm(k)}k=1,…,
K. The proportion of the sampled permutations with distance larger
than the observed distance is taken as the p-value of the one-sided test,
pm ¼
1
K
∑Kk¼1I d
kð Þ
m ≥dm
 
:
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We selected gene sets from the biological processes of the Gene
Ontology (GO) [20]. In order to select a collection of GO terms that
were relatively speciﬁc yet not too narrow, we used a heuristic proce-
dure that examines the number of ENTREZ gene IDs assigned to each
term and its direct descendants. We ignored all terms with less than
10 assigned human genes. Starting from the term “biological_process”,
we examined if 40% of the term's genes (70% if the term contains less
than 500 genes) were assigned to its children terms. If the answer
was yes, we abandoned the term for being too broad, and examined
its children terms one-by-one using the same criterion; if the answer
was no, we kept the term in the ﬁnal collection. We continued this pro-
cedure until all biological process terms were exhausted. Due to the
structure of theGO system, a small fraction of the terms in the collection
had ancestor–descendant relations, inwhich case the descendant terms
were eliminated.
2.6. Simulations
To achieve realistic correlation structures in simulated data, we
randomly sampled 1000 genes from the yeast cell cycle dataset [21],
and computed the Cholesky decomposition of the correlation matrix
between genes. In every simulation, we ﬁrst generated a control
data matrix and a treatment data matrix. In each matrix, the gene ex-
pression values were independently drawn from the standard normal
distribution. Then we multiplied each matrix with the Cholesky
square root of the cell cycle data to achieve an overall distribution
of correlations similar to the real data. In all the simulations, 1000
genes were simulated, and different sample sizes (50, 100, 200 sam-
ples per group) were simulated. Four gene set sizes were considered:
10, 20, 50 and 100 genes.
To simulate a gene set of size m, we ﬁrst randomly drew a seed
gene, and found its top 50 (or 2m, whichever is larger) neighbors
based on correlation coefﬁcient, including itself. Then we randomly
selected m genes from them. This way the expressions within the
simulated gene set were reasonably coherent, yet not too tightly cor-
related [12]. First, to conﬁrm that the size of the tests were correct, we
tested for differential coordination of one gene set, and between a
pair of gene sets, without any further manipulation of the data. Sec-
ondly, to assess the statistical power of GSDCA to detect differential
coordination of a gene set, and the power to select contributing
genes, we performed the simulation in two ways. In each simulation,
the data in the treatment data matrix were further manipulated,
while the control data matrix was unchanged. (1) We added noise
at different signal to noise ratio (deﬁned as the ratio between the var-
iances of signal and noise, S/N=2, 1, 0.5, or 0) to the expression
values of a portion (10%, 20%, 30%, 40%, or 50%) of the genes in the
gene set. Note that this S/N considers all pre-manipulation values as
signal. The data generation process introduces a certain level of base-
line noise, for which we cannot determine the exact S/N because the
true noise level of the cell-cycle data is unknown. (2) We replaced the
expression values of a portion (10%, 20%, 30%, 40%, or 50%) of the
genes in the gene set with those of other randomly selected genes,
plus different levels of noise (S/N=2, 1, 0.5, or 0). When S/N=0,
the results from the two scenarios should converge as the expression
values were replaced with pure noise and the selected genes lost cor-
relation with other genes. Thirdly, to assess the power of GSDCA to
detect differential coordination between a pair of gene sets, we ﬁrst
drew two non-overlapping gene sets, and then replaced the expres-
sion values of a portion (10%, 20%, 30%, 40%, or 50%) of the genes in
one gene set with those of randomly selected genes from the other
gene set, plus different levels of noise (S/N=2, 1, 0.5, or 0). Again
this manipulation was only done to the treatment data matrix,
while the control data matrix was unchanged. At each parameter set-
ting, the simulation was run 100 times.3. Results and discussions
3.1. Simulation results
When GSDCA was applied between matrices with similar correla-
tion structure, at the alpha cutoff of 0.05, 5.7% of the gene sets were
called signiﬁcant, 5.8% of gene set pairs were called signiﬁcant, and
5.7% of the genes were called signiﬁcant. There was no trend associated
with sample size or gene set size. These results conﬁrmed that the size
of the test is correct, with a very slight inﬂation of false positives.
We then considered the statistical power of GSDCA to detect the dif-
ferential coordination of a gene set (Fig. 1). The power is deﬁned as the
probability to call the gene set as signiﬁcantwhen it is truly differential-
ly coordinated. In Fig. 1, each column represents a different sample size,
and each row represents a different gene set size. Two gene set sizes are
shown here.More complete result can be found in the Supporting Fig. 3.
The statistical power is plotted against signal to noise ratio (S/N). The
left half (gray) of each plot shows the results from adding different
levels of noise to the original gene expression values in the treatment
data matrix. The effect of adding noise is causing the selected genes to
lose correlation with other genes. This scenario represents situations
where genes in certain pathways become dysregulated, which often
happens in cancer [22].When a gene becomes constitutively expressed,
repressed, or simply uncontrolled, its variation in microarray data is
mostly from biological/measurement noise, and its correlations with
other genes become low. In this scenario, we can clearly see that the
power rose along with the increase of noise. At higher S/N level (left),
little noise was added to the original expression values. Thus the GIOC
proﬁle of the gene set changed little, and the statistical power of ﬁnding
the differential coordination is close to zero. With the increase of noise,
i.e. decrease of S/N ratio (right), the gene set's GIOC proﬁle changed
more and the power of identifying the differential coordination rose.
However, the power was still limited at S/N=0, when the expression
of a subset of genes were replaced by pure noise. In this scenario the
gene set lost part of its transcriptional connections to the rest of the
transcriptome, yet didn't gain new connections. In addition, as the sim-
ulated gene sets were relatively coherent, i.e. genes within the gene set
were correlated, when gene A in the gene set lost correlationwith gene
B outside the gene set, gene C in the same gene set could still be corre-
lated with gene B, thus the change of the GIOC proﬁle of the gene set
was limited.
On the right half of each sub-plot is the situation where the ex-
pressions of the genes were replaced by those of randomly selected
genes outside the gene set plus different levels of noise. We can see
that with the increase of S/N, meaning a portion of the genes inside
the gene set became more and more correlated with some outside
genes, the power continued to rise. When the sample size and/or
the proportion of genes that change expression were reasonably
large, the statistical power of detecting the differential coordination
approached one.
Fig. 2 shows the power of GSDCA to selectmajor contributing genes.
Two gene set sizes are shown here. More complete result can be found
in the Supporting Fig. 4. At the sample size of 100/group or higher, the
power was high when the genes were replaced by noise, and stayed
highwhen the signal of another genewas incorporated.When the sam-
ple size was small (50/group), the power was larger for smaller gene
sets, which is expected as the contribution of each gene is large when
the gene set is small. At the same time, for the portion of genes that
didn't change correlation patterns, the size of the test remained correct
— 5.9% of unchanged genes were called signiﬁcant, and there was no
clear trend associated with sample size or gene set size (Supporting
Fig. 5).
Fig. 3 shows the power of GSDCA to detect differential coordination
between a pair of gene sets, when a subset of their genes become corre-
lated. The power rose with the increase of gene set size, sample size,
and/or the proportion of genes becoming highly correlated. More
Fig. 2. The statistical power of GSDCA to identify contributing genes to the differential coordination of a gene set in simulation. Each column represents a different sample size. Each
row represents a different size of gene sets. The statistical power is plotted against signal to noise ratio (S/N) for the portion of genes to which noise was added. Presented are the
merged results from two sets of simulations. Left half (gray) of each plot: different levels of noise were added to original gene expression values; right half (white): the expressions
of a portion of genes were replaced by those of genes outside the gene set (randomly selected) plus different levels of noise. The two sets of results converge when S/N=0, where
the expressions of some genes were replaced by random noise. The alpha cutoff of 0.05 was used.
Fig. 1. The statistical power of GSDCA to identify differentially coordinated gene sets in simulation. Each column represents a different sample size. Each row represents a different
size of gene sets. The statistical power is plotted against signal to noise ratio (S/N) for the portion of genes to which noise was added. Presented are the merged results from two sets
of simulations. Left half (gray) of each plot: different levels of noise were added to original gene expression values; right half (white): the expressions of a portion of genes were
replaced by those of genes outside the gene set (randomly selected) plus different levels of noise. The two sets of results converge when S/N=0, where the expressions of some
genes were replaced by random noise. The alpha cutoff of 0.05 was used.
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Fig. 3. The statistical power ofGSDCA to identify differentially coordinated gene set pairs in simulation. Each column represents a different sample size. Each row represents a different size
of gene sets. The statistical power is plotted against signal to noise ratio (S/N). The expression of a portion of genes in one gene set were changed to that of genes in the other gene set, plus
different levels of noise. The alpha cutoff of 0.05 was used.
473T. Yu, Y. Bai / Genomics 98 (2011) 469–477complete result can be found in the Supporting Fig. 6. Biological regula-
tion at the gene set level is complex, and our simulation only represents
a few of the many possibilities. In the following text, we demonstrate
the value of the approach using real data analyses.
3.2. Real data analysis — GSE18864
Using the heuristic GO term selection procedure, we selected 577
biological process terms that contain a total of 10,455 genes, which ac-
count for 73.5% of all genes with biological process annotations. The full
list of the selected gene sets are in Supporting Table 1. Given a dataset
with two treatment groups, we ﬁrst computed the GIOC function of
every gene set in each treatment group. Secondly, for every gene set,
we found the distance between its GIOC functions in the two treatment
groups, and the signiﬁcance level using the randomization test. Thirdly,
after the most signiﬁcant gene sets were selected, we examined their
changes of coordination with all other gene sets under study. Fourthly,
we identiﬁed the most inﬂuential genes in the differential coordination
to help elucidate the mechanisms. Along with the GSDCA analysis, we
also performed regular gene set analysis using one of the leading
methods — GSA by Efron and Tibshirani [2]. Notice the purpose of in-
cluding GSA results is not for direct competition, as the two methods
aim at different goals. Rather, we wish to show that GSDCA extracts ad-
ditional information that is not revealed by regular gene set analyses
that focus on ﬁrst-order relations.
The ﬁrst dataset we analyzedwas the GSE18864 dataset downloaded
from the Gene Expression Omnibus (GEO; GSE18864) [23], which com-
pares the gene expression of sporadic triple negative breast cancers
(TNBC) against other types of breast cancer. TNBC is characterized by
the lack of expression of estrogen receptor (ER, encoded by ESR1 and
ESR2), progesterone receptor (PgR, encoded by PGR), and the human
epidermal growth factor receptor 2 (ERBB2) [24]. The data contains 24
TNBC samples and51 samples frombreast cancers of all subtypes.We se-
lected the probesets with known ENTREZ Gene IDs. When a gene was
represented by more than one probesets, we merged the correspondingprobesets by taking the average expression values. The ﬁnal data matrix
contained 19,622 rows (genes) and 75 columns (samples). The GSDCA
p-values for a big proportion of the gene setswere quite small, indicating
large global changes of co-expression patterns. On the other hand, the
GSA p-values appeared to be uniformly distributed, indicating no strong
ﬁrst-order gene set differential expression (Supporting Table 2).
We transformed the p-values using Benjamini and Yekutieli's false
discovery rate (BY FDR),which is a stringentmethod that dealswith de-
pendency between tests [25]. We focus our discussion here on the gene
setswith BY FDR less or equal to 0.05 (Table 1).Weﬁrst noticed that 7 of
the 27 gene sets (Table 1; superscript 1) contained at least one of the
three receptors that characterize TNBC. Interestingly, although TNBC is
characterized by the lack of expression of these receptors [24], only
one of the 7 gene sets (GO:0048384, retinoic acid receptor signaling
pathway, p-value 0.035) showed ﬁrst-order relationship with the can-
cer type according to the GSA p-values. This indicates a more complex
regulatory mechanism behind the phenotype. In ﬁve of the seven
gene sets, a TNBC-related receptor, either ESR1 or PGR, was identiﬁed
as one of the major contributing genes to the differential coordination
(Table 1; Supporting Table 4). ESR2 and ERBB2 appeared to play a less
important role in the differential coordination.
Secondly, four cell-cycle/DNA replication related gene sets were
among the top 27 gene sets (superscript 2), which could be related to
the different growth characteristics of TNBC [26]. Some of the genes
known to be associated with TNBC, or breast cancer in general, were
among the top contributing genes to these gene sets' differential coordi-
nation (Supporting Table 4). They include RAD51,whose function tends
to be lower in TNBC [27]; BLM andMAD2L1,whose levels are associated
with the prognosis of ER-negative breast cancers [28]; ATM,whose level
is reduced in BRCA1/BRCA2-deﬁcient breast cancer and TNBC [29]; and
RAD51B, a genetic risk factor of breast cancer [30]. Among the other top
gene sets, we also found many connections with TNBC or breast cancer
in general.We brieﬂy list some examples here. TNBC is characterized by
enhanced angiogenesis, which involves genes in blood vessel remodel-
ing such as VEGFA (superscript 3) [31]. The relationship between
Table 1
Gene sets with BY FDRb0.05 in the GSE18864 dataset.
GO term Name TNBC receptor
genes involved
GSDCA
p-value
BY
FDR
GSA
p-value
GO:0030534 Adult behavior 0 0 0.032
GO:0001974 3Blood vessel
remodeling
0 0 0.178
GO:0033059 4Cellular pigmentation 0 0 0.027
GO:0043623 Cellular protein
complex assembly
0 0 0.095
GO:0006333 2Chromatin assembly
or disassembly
0 0 0.164
GO:0042384 5Cilium assembly 0 0 0.002
GO:0000578 6Embryonic axis
speciﬁcation
0 0 0.02
GO:0030855 1Epithelial cell
differentiation
PGRa 0 0 0.143
GO:0030520 1Estrogen receptor
signaling pathway
ESR1a, ESR2 0 0 0.080
GO:0008585 1Female gonad
development
PGRa 0 0 0.207
GO:0042593 Glucose homeostasis 0 0 0.057
GO:0006516 Glycoprotein catabolic
process
0 0 0.346
GO:0007030 Golgi organization 0 0 0.357
GO:0001889 1Liver development ERBB2 0 0 0.149
GO:0007093 2Mitotic cell cycle
checkpoint
0 0 0.387
GO:0022602 1Ovulation cycle
process
PGRa 0 0 0.256
GO:0007422 1Peripheral nervous
system development
ERBB2 0 0 0.147
GO:0045666 7Positive regulation of
neuron differentiation
0 0 0.041
GO:0009791 8Post-embryonic
development
0 0 0.143
GO:0009954 Proximal/distal pattern
formation
0 0 0.221
GO:0046320 Regulation of fatty acid
oxidation
0 0 0.494
GO:0048384 1Retinoic acid receptor
signaling pathway
ESR1a 0 0 0.035
GO:0006829 9Zinc ion transport 0 0 0.254
GO:0000077 2DNA damage
checkpoint
0.00025 0.037 0.334
GO:0045444 Fat cell differentiation 0.00025 0.037 0.128
GO:0007126 2Meiosis 0.00025 0.037 0.489
GO:0060491 Regulation of cell
projection assembly
0.00025 0.037 0.264
a TNBC receptor genes identiﬁed as major contributors to the differential coordina-
tion of the gene sets. All ﬁve p-values were ≤0.0015.
Table 2
Top 25 differentially coordinated gene sets in response to MTX treatment.
GO term Name GSDCA
p-value
GSA
p-value
GO:0031929 2TOR signaling pathway 0.001 0.245
GO:0019794 3Nonprotein amino acid metabolic process 0.002 0.168
GO:0002718 1Regulation of cytokine production during
immune response
0.002 0.030
GO:0042228 1Interleukin-8 biosynthetic process 0.002 0.018
GO:0002444 1Myeloid leukocyte mediated immunity 0.002 0.007
GO:0030574 4Collagen catabolic process 0.003 0.152
GO:0009620 1Response to fungus 0.004 0.114
GO:0009303 rRNA transcription 0.006 0.465
GO:0007156 5Homophilic cell adhesion 0.008 0.481
GO:0007009 6Plasma membrane organization 0.008 0.03
GO:0042092 1T-helper 2 type immune response 0.009 0.02
GO:0006944 Membrane fusion 0.01 0.104
GO:0006805 1Xenobiotic metabolic process 0.01 0.338
GO:0006968 1Cellular defense response 0.011 0.006
GO:0009595 1Detection of biotic stimulus 0.012 0.137
GO:0002889 1Regulation of immunoglobulin mediated
immune response
0.012 0.019
GO:0042742 1Defense response to bacterium 0.013 0.015
GO:0006888 ER to Golgi vesicle-mediated transport 0.013 0.265
GO:0042375 Quinone cofactor metabolic process 0.014 0.267
GO:0046717 9Acid secretion 0.015 0.111
GO:0046131 7Pyrimidine ribonucleoside metabolic process 0.017 0.046
GO:0006954 1Inﬂammatory response 0.017 0.018
GO:0006754 8ATP biosynthetic process 0.018 0.295
GO:0051262 Protein tetramerization 0.019 0.094
GO:0032655 1Regulation of interleukin-12 production 0.021 0.041
474 T. Yu, Y. Bai / Genomics 98 (2011) 469–477pigmentation and breast cancer is reviewed in [32], and polymorphisms
in pigmentation gene OCA2 have been associated with ER-negative
breast cancer survival (superscript 4) [33]. Cilia abnormalities have
been reported in breast cancer (superscript 5) [34]. A large portion of
the genes in embryonic axis speciﬁcation are involved in estrogen-de-
pendent transcription and cancer (superscript 6) [35]. It has been docu-
mented some growth factors in positive regulation of neuron
differentiation, including EPO and BDNF, are related to breast cancer
progression (superscript 7) [36]. The apoptosis regulating BCL2 family
and the hedgehog signaling genes of the embryonic development pro-
cess are known to be associated with breast cancer (superscript 8)
[37]. The aberrant expression of some zinc transporters were linked to
the progression of breast cancer (superscript 9) [38].
We then identiﬁed gene sets that showed differential coordination
with those listed in Table 2 (BY FDRb0.05; Fig. 4; Supporting Table 3).
Because the gene sets in this study accounted for 74% of ENTREZ
genes with biological process annotation, and 53% of all ENTREZ genes
measured on the array, the graph (Fig. 4) only provides partial explana-
tion to the results in Table 1. We observed a clear pattern in the distri-
bution of the red (higher coordination in TNBC) and green (lower
coordination in TNBC) edges. Interestingly, two gene sets showedboth increased and decreased coordination. They were zinc ion trans-
port (GO:0006829) and positive regulation of neuron differentiation
(GO:0045666). Three gene sets were connected by a large number of
green edges. They include the cell-cycle-related gene set DNA damage
checkpoint (GO:0000077), as well as Golgi organization (GP:0007030)
and glycoprotein catabolic process (GO:0006516). Three gene sets
were connected by a large number of red edges. Two of them
(GO:0030520, GO:0048384) were signaling pathways and contained
ESR1, which was a major contributing gene for both gene sets. The
other was mitotic cell cycle checkpoint (GO:0007093). The major con-
tributing genes for this gene set included BLM and MAD21L1, whose
levels are associated with the prognosis of ER− breast cancer (Support-
ing Table 4) [28].
Genes that were major contributors to the differential coordination
(p-valueb0.05) are listed in Supporting Table 4. Two of the receptors
that characterize TNBC, ESR1 and PGR, were among the top gene lists
of ﬁve gene sets. Besides the genes we discussed above, among the
known genes associated with TNBC or breast cancer in general, a num-
ber of them, such as ARL6, HOXB6, HOXD8, BDNF, BCL2 and BMP4,were
also identiﬁed as major contributors to the differential coordination.3.3. Real data analysis — GSE10255
The second dataset we studied was the gene expression in primary
acute lymphoblastic leukemia (ALL) associated with methotrexate
(MTX) treatment [39]. The major clinical outcome is the reduction of
circulating leukemia cells after initialMTX treatment. Againwe selected
the probesets with known ENTREZ Gene IDs. When a gene was repre-
sented bymore than one probesets, wemerged the corresponding pro-
besets by taking the average expression values. The data matrix
contained 12,704 rows (genes) and 161 columns (samples). In order
to identify differential coordination associated with MTX treatment re-
sponse, we selected samples falling into the top- and bottom-quartiles
in the clinical outcome — reduction of circulating leukemia cells. Thus
82 samples were used in the analysis.
Using the one-sided randomization test, we tested the hypothesis
that a gene set's coordinationwith the entire transcriptomewas different
Fig. 4. Differences in gene set coordination between the TNBC and other types of breast cancer. Node labels are GO accession numbers with preceding zeroes omitted. Cyan nodes:
differentially coordinated gene sets with BY FDRb0.05; gray nodes: other gene sets. Green solid edges: higher coordination in other types of breast cancer; red dashed edges: higher
coordination in TNBC. The plot was generated using Cytoscape [50].
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sample size, and possibly the subtlety of the changes in gene expression
dynamics, the p-values were not extremely small to undergo stringent
FDR adjustment that considers dependency between tests. We used
the nominal p-values as a ranking tool and picked the top 25 differential-
ly coordinated gene sets (Table 2). For the complete list of p-values of all
the gene sets, please refer to Supporting Table 5. Again the GSA p-values
were close to uniformly distributed showing limited ﬁrst-order relation-
ship with the clinical outcome (Supporting Table 5).
Twelve (48%) of the top 25 gene sets were associated with stimulus
response and cytokine production (Table 2; gene sets labeled with su-
perscript 1), while only 13.8% of all the 577 gene sets under study
were related to such processes. This is consistent with the immunosup-
pressive effect of MTX [40]. A number of these gene sets showed both
differential coordination and differential expression, as evidenced by
the GSA p-values.
Most notably, the top gene set found by GSDCA was the TOR signal-
ing pathway (Table 2; superscript 2). It was documented that a number
of genes in the TOR pathway play important roles in ALL development
and drug resistance [41]. More importantly, synergistic effect was
found between mTOR inhibitors and MTX in clinical trial [42]. This
gene set was not signiﬁcant in the GSA result, which supports the argu-
ment that GSDCA extracts additional useful results from the data by uti-
lizing different information than regular gene set analysis. The second
most signiﬁcant gene set found by our method, nonprotein amino
acid metabolic process (Table 2; superscript 3), involves the metabo-
lism of citrulline, ornithine and beta-alanine. The concentrations of or-
nithine and citrulline in gut tissues were found to be impacted by
MTX treatment [43]. Among the other top gene sets, we also found
many connections with MTX and/or ALL development. We brieﬂy list
some examples here. A few genes in collagen metabolism were found
to be associated with leukemia [44], and the overall expression level
of collagen increases with MTX treatment (superscript 4) [45]. Several
cellular adhesionmolecules are known to be inﬂuenced byMTX (super-
script 5) [40]. In addition, diversity in adhesionmolecule levels was ob-
served in other types of leukemia [46]. A number of proteins in the
membrane organization process are inﬂuenced by leukemia (super-
script 6) [44,47]. Pyrimidine metabolism is known to be affected by
MTX due to its inhibition of the related purine metabolic pathway
(superscript 7) [48]. Genes in the ATP biosynthesis pathway werefound to be differentially expressed in a combination therapy involving
MTX (superscript 8) [49].
We then identiﬁed gene sets that showed differential coordination
(p-valueb0.005) with those listed in Table 2 (Fig. 5). With the increase
of MTX response, seven of the top 25 gene sets, six of which belonging
to the stimulus response system, showed decreased coordination (red
dashed edges) with other gene sets. A large proportion of the pairs
showed clear functional relationships. For example, 76.7% of the stimu-
lus response and cytokine production gene sets associated with any of
the top 25 gene sets were actually associated with one of the 12 stimu-
lus response and cytokine production gene sets. The full list of the gene
set pairs is provided in Supporting Table 6.
We further identiﬁed major gene contributors to the top differen-
tially coordinated gene sets (Supporting Table 7). Interleukins and
their receptors, especially IL10, appeared to contribute to the differen-
tial coordination of multiple gene sets. The gene set “acid secretion”
wasdifferentially coordinated (Table 1, superscript 9), yet no clear func-
tional link to ALL or MTX was documented. The gene-level result pro-
vided an explanation — among the 8 genes of the gene set, 2 were
shared with inﬂammatory response. One of these two genes, ANXA1,
was highly signiﬁcant in the test of single gene contributors (p-value
0.002).
In this manuscript, we presented a method to detect differential co-
ordination at the gene set level, together with follow-up analysis
methods. Our GSDCA method is based on the genome-wide index of
correlation (GIOC) proﬁle of a gene set, which utilizes the correlation
structure between a gene set and all the genes measured in the array.
Given that a large portion of the genes are without functional annota-
tion, and a lot of other genes may have incomplete annotations, a
gene set proﬁle that utilizes all measured genes can better capture the
useful information in the data.
In this study, we used a two-step procedure to analyze the datasets.
First, we examined whether a gene set's GIOC proﬁle changed signiﬁ-
cantly between treatment groups. Secondly, for those selected gene
sets from the ﬁrst step, we further explored their change of coordina-
tionwith other gene sets, in order to better understand themechanistic
changes at the functional group level. In this process, we avoided testing
for signiﬁcance of gene set pairs within one treatment group. The rea-
son is that if we were to use randomization test for signiﬁcance within
one treatment group, wewould have to resort to permuting gene labels,
Fig. 5. Changes in gene set coordination between the low MTX response group and the high MTX response group. Node labels are GO accession numbers with preceding zeroes
omitted. Cyan nodes: top 25 differentially coordinated gene sets; gray nodes: other gene sets. Green solid edges: increased coordination in high MTX response group; red dashed
edges: decreased coordination in high MTX response group. The plot was generated using Cytoscape [50].
476 T. Yu, Y. Bai / Genomics 98 (2011) 469–477which is plagued by issues of not preserving correlation structure and
favoring gene sets with certain characteristics [1,10].
4. Conclusion
Overall, the proposed method is explorative and hypotheses-
generating. It could help biologists identify potential functional groups/
pathways that are associated with disease progression and/or drug re-
sponse. Biological regulations at the gene set level are complex. Analyzing
gene set level differential coordination may lead to insights into the data
that complement results generated by traditional gene set analyses that
focus on ﬁrst-order relationships between gene sets and the clinical
outcome.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.ygeno.2011.09.001.
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